CRSP Overview
Upcoming Projects (CRSP)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CRSP)
-
Discussing how payers are strategizing pricing and reimbursement for cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease.
Tickers: VRTX, BLUE, CRSP
Executed On: Sep 11, 2024 at 04:00 PM EDT -
A Third Look: Discussing prime editing, how it compares to CRISPR/Cas9, and it's potential in future therapeutics.
Tickers: PRME, VRTX, CRSP
Executed On: Jun 21, 2024 at 09:00 AM EDT -
A Second Look: Discussing prime editing, how it compares to CRISPR/Cas9, and it's potential in future therapeutics.
Tickers: PRME, VRTX, CRSP
Executed On: May 23, 2024 at 03:00 PM EDT -
Discussing prime editing, how it compares to CRISPR/Cas9, and it's potential in future therapeutics.
Tickers: PRME, VRTX, CRSP
Executed On: May 14, 2024 at 04:00 PM EDT -
A Third Look: Discussing the potential of gene therapies in SCD such as Vertex and CRISPR Therapeutics' CASGEVY (Exa-cel) and bluebird bio's LYFGENIA (lovotibeglogene autotemcel)
Tickers: VRTX, CRSP, BLUE
Executed On: May 02, 2024 at 02:00 PM EDT -
Follow-up Discussing how payers are strategizing pricing and reimbursement for cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease.
Tickers: VRTX, BLUE, CRSP
Executed On: May 02, 2024 at 10:00 AM EDT -
A Second Look: Discussing the potential of gene therapies in SCD such as Vertex and CRISPR Therapeutics' CASGEVY (Exa-cel) and bluebird bio's LYFGENIA (lovotibeglogene autotemcel)
Tickers: VRTX, CRSP, BLUE
Executed On: May 01, 2024 at 02:00 PM EDT -
Discussing the potential of gene therapies in SCD such as Vertex and CRISPR Therapeutics' CASGEVY (Exa-cel) and bluebird bio's LYFGENIA (lovotibeglogene autotemcel).
Tickers: VRTX, CRSP, BLUE
Executed On: Apr 24, 2024 at 12:00 PM EDT -
A Second Look: Discussing how payers are strategizing pricing and reimbursement for recently approved cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease.
Tickers: VRTX, BLUE, CRSP
Executed On: Dec 21, 2023 at 01:00 PM EST -
Discussing how payers are strategizing pricing and reimbursement for recently approved cell-based gene therapies, Casgevy and Lyfgenia, for the treatment of sickle cell disease.
Tickers: VRTX, BLUE, CRSP
Executed On: Dec 19, 2023 at 01:00 PM EST -
An up to date look at exagamglogene autotemcel(exa-cel) in patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: VRTX, CRSP, BLUE
Executed On: Sep 07, 2023 at 10:00 AM EDT -
A second look: Discussing the potential of gene therapies such as exagamglogene autotemcel(exa-cel) in patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: VRTX, CRSP, BLUE
Executed On: Apr 14, 2023 at 09:00 AM EDT -
A review of EDIT-301 as an experimental cell therapy medicine for the treatment of severe sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: EDIT, VRTX, BLUE, CRSP
Executed On: Mar 13, 2023 at 02:00 PM EDT -
Discussing the potential of gene therapies such as exagamglogene autotemcel(exa-cel) in patients with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT)
Tickers: VRTX, CRSP
Executed On: Feb 07, 2023 at 10:00 AM EST -
A Final look - Sickle Cell Update | New gene editing data from EHA 2022
Tickers: CRSP, VRTX
Executed On: Jun 28, 2022 at 12:45 PM EDT -
A second look - Sickle Cell Update | New gene editing data from EHA 2022
Tickers: CRSP, VRTX
Executed On: Jun 16, 2022 at 05:30 PM EDT -
Sickle Cell Update | New gene editing data from EHA 2022
Tickers: CRSP, VRTX
Executed On: Jun 15, 2022 at 04:30 PM EDT
Upcoming & Overdue Catalysts (CRSP)
-
Don’t see a catalyst related to the company you care about? Create your own!
Strategic Initiatives (CRSP)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
